What is the procedure for testing for Venereal Disease Research Laboratory (VDRL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

VDRL Testing Procedure for Syphilis Diagnosis

The Venereal Disease Research Laboratory (VDRL) test is a nontreponemal test that should be performed in conjunction with treponemal-specific tests for accurate diagnosis of syphilis, as no single test alone is sufficient for definitive diagnosis. 1, 2

VDRL Testing Procedure

  • VDRL detects nonspecific antiphospholipid antibodies produced by the host in response to phosphatidylcholine taken up from mammalian tissue by Treponema pallidum 3
  • Results should always be reported quantitatively as titers, which correlate with disease activity 3, 2
  • A fourfold change in titer (equivalent to two dilutions) indicates a clinically significant difference when monitoring treatment response 3, 2
  • For cerebrospinal fluid (CSF) testing, the VDRL-CSF is the standard serologic test for neurosyphilis diagnosis 1

Diagnostic Algorithm

  • Initial screening should include both nontreponemal (VDRL or RPR) and treponemal-specific tests (FTA-ABS, TP-PA) 3, 2
  • When lesions are present, darkfield examinations and direct fluorescent antibody tests of lesion exudate should be prioritized as definitive diagnostic methods 2
  • Sequential serologic tests should be performed using the same testing method (e.g., VDRL or RPR), preferably by the same laboratory 1, 2

VDRL vs. RPR Comparison

  • VDRL and RPR are equally valid assays, but their quantitative results cannot be compared directly 1, 4
  • RPR titers often are slightly higher than VDRL titers 1, 4
  • For neurosyphilis diagnosis, CSF-VDRL is more sensitive than CSF-RPR (71.8% vs. 56.4%) 1, 5
  • CSF-VDRL has a specificity of 98.3% for neurosyphilis diagnosis 1, 5

Neurosyphilis Diagnosis

  • No single test can diagnose all cases of neurosyphilis 1
  • Diagnosis typically requires a combination of:
    • Reactive serologic test results
    • Abnormal CSF cell count (>5 WBCs/mm³) or protein
    • Reactive VDRL-CSF 1
  • CSF-VDRL may be nonreactive when neurosyphilis is present 1, 6
  • Some experts recommend performing an FTA-ABS test on CSF, which is less specific but more sensitive 1, 7

Sensitivity and Specificity

  • VDRL sensitivity varies by stage of syphilis: approximately 88.5% in primary syphilis, 100% in secondary syphilis, 82-100% in latent early syphilis, and 61-75% in latent late syphilis 3
  • For neurosyphilis, CSF-VDRL has a sensitivity of 71.8% and specificity of 98.3% 1, 5
  • Treponemal tests like TP-PA have higher sensitivity (86%) than VDRL (71%) for primary syphilis diagnosis 8

Important Considerations and Pitfalls

  • False-positive VDRL results can occur in various conditions, including HIV infection, hepatitis B, hepatitis C, autoimmune diseases, and pregnancy 3, 4
  • HIV-infected patients may have abnormal serologic test results (unusually high, low, or fluctuating titers) 1
  • Nontreponemal tests usually become nonreactive after treatment, but some patients develop a "serofast reaction" with persistent low titers 1, 4
  • Treponemal tests typically remain reactive for life regardless of treatment or disease activity 1, 2
  • Using only one type of test (either nontreponemal or treponemal) can lead to misdiagnosis 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Syphilis Diagnosis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnóstico y Manejo de la Sífilis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Syphilis Diagnosis and Monitoring using Rapid Plasma Reagin

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.